ArticleJournal for immunotherapy of cancer2022

Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.

Ganesan Ramamoorthi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.